Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determ…

Focal SeizureEpilepsyFocal Epilepsy

Estimated

~$10 – $8,750

Rapport Therapeutics Inc.NCT07563881

Phase 1

A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures

Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or …

Focal Seizures

Estimated

~$10 – $8,750

Jazz PharmaceuticalsNCT07233239

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determ…

Focal SeizureEpilepsyFocal Epilepsy

Estimated

~$10 – $8,750

Rapport Therapeutics Inc.NCT07594119

Phase 2

A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)

Focal Seizure

Estimated

~$10 – $7,500

Praxis Precision MedicinesNCT06999902

Phase 2

An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to deter…

Focal EpilepsyEpilepsyRefractory Focal Epilepsy+3 more

Estimated

~$10 – $8,750

Rapport Therapeutics Inc.NCT07219407